Cenicriviroc

Two years on, Allergan’s $1.7B NASH drug still looks weak — at best
Endpoints
Fri, 09/22/17 - 11:16 am
Allergan
NASH
Novartis
Cenicriviroc
Should Gilead Sciences Be Worried About Allergan?
Motley Fool
Mon, 04/24/17 - 09:59 am
Gilead Sciences
Allergan
NASH
GS-4997
Cenicriviroc
evogliptin
Allergan, Novartis ink NASH partnership
BioPharma Dive
Wed, 04/19/17 - 10:02 am
Allergan
Novartis
NASH
Cenicriviroc
LJN452
Allergan May Have Outbid Gilead For Tobira, Setting The Backdrop For A Showdown In NASH
Seeking Alpha
Wed, 10/19/16 - 10:44 am
Allergan
Gilead Sciences
Tobira
NASH
Cenicriviroc
Allergan Enters the Attractive NASH Market
Market Realist
Thu, 10/6/16 - 09:26 am
Allergan
NASH
Cenicriviroc
Tobira Therapeutics